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1. Introduction  
Tuberculosis is an ancient disease. It was recognised and described by Hippocratus  (460–390 
BCE) and Galen (2nd–3rd century CE) in the western Classical World (Xarchus & Bourandas, 
2003), ancient Egypt, India and the Far East (Morse, 1961). The obvious symptoms that 
attracted attention were the late outcomes of skeletal tuberculosis, where collapsed vertebrae 
led to scoliosis and Pott's disease, plus the symptoms associated with pulmonary tuberculosis, 
such as fever, weight loss and haemoptysis (coughing up blood). In the UK, tubercular lesions 
of the lymph glands (cervical lymphadenitis) were formerly termed scrofula, or the King's evil, 
and tubercular skin lesions were described as Lupus vulgaris or tuberculous chancre. The 
palaeopathology of ancient skeletal remains, together with classical and historical reports, 
demonstrate that tuberculosis occurred in prehistory. However, tuberculosis is still the greatest 
cause of death from any single infectious disease in the world today, with over one third of the 
global population infected and an estimated 1.7 million deaths from the disease in 2009 (WHO, 
2010). Therefore it is essential to understand the nature of tuberculosis in the past: its 
distribution, spread and relationship to human society. 
The disease is caused by members of a group of very closely related bacteria, termed the 
Mycobacterium tuberculosis complex (MTBC). These are obligate parasites and have the 
ability to subvert the cell-mediated immune system of the host and to survive and multiply 
within macrophages. Most human infections are caused by Mycobacterium tuberculosis and 
are usually acquired via the aerosol route from an active case of pulmonary tuberculosis. 
Infectious aerosols lodge in the alveoli but, in the majority of cases, the bacilli are controlled 
by the host immune system to form a granuloma and the disease remains latent. Infection 
can also occur by ingestion – milk or meat from an infected animal can give rise to human 
zoonotic cases of tuberculosis caused by Mycobacterium bovis or other members of the MTBC. 
In endemic areas, infection takes place in early life and may remain latent throughout a 
lifetime or become re-activated due to lowered host resistance caused by physical or mental 
stress, immunosuppression or extreme age (Rustad et al., 2009). Active primary tuberculosis, 
estimated to occur in 2–5% of cases, normally causes lymphadenitis and subsequent spread 
via the blood stream can cause meningitis or miliary tuberculosis (Grange & Zumla, 2009). 
Post-primary tuberculosis is estimated to occur in a similar proportion of people and these 
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individuals in ancient and historical times would be the recognisable cases of skeletal 
tuberculosis. Therefore, it is highly significant that these historical cases, diagnosed by 
skeletal pathology, represent only around 5% of the total number of individuals with the 
disease. 
Because of their very slow growth-rate and clinical significance, the MTBC was one of the 
first groups of microorganisms to benefit from the introduction of the polymerase chain 
reaction (PCR) and molecular diagnostics. This led to a an understanding of the 
epidemiology of tuberculosis (Reed et al., 2009; Smith et al., 2006), the evolution of the 
MTBC (Brosch et al., 2002; Ernst et al., 2007; Gordon et al., 2009; Gutierrez et al., 2005) and to 
the realisation that particular lineages of M. tuberculosis are associated with the country of 
origin of their human hosts (Hershberg et al., 2008; Hirsh et al. 2004; Wirth et al., 2008). Total 
sequencing of the genomes of M. tuberculosis (Cole et al., 1998), M. bovis (Garnier et al., 2003) 
and attenuated M. bovis Bacille Calmette-Guérin (BCG) vaccine strains (Pan et al., 2011; Seki 
et al., 2009) has elucidated the relationship between MTBC strain, lineage and pathogenicity. 
We now understand that the MTBC represents a clonal expansion of pathogenic strains or 
ecotypes (Smith et al., 2006) each of which is associated with a parallel clonal expansion of 
their mammalian hosts (Maiden, 2009). 
The MTBC is distinct from the large number of environmental mycobacteria, which are 
generally non-virulent or cause opportunist infections in hosts, especially those with 
increased susceptibility. A characteristic feature of the mycobacteria is their cell envelope, 
which contains a high proportion of lipid-rich molecules, such as mycolic acids and 
phthiocerol dimycocerosate waxes (Minnikin, 1982; Minnikin et al., 2002). These result in a 
hydrophobic bacterial cell wall with decreased permeability and susceptibility to 
degradation, that may partially explain the very slow growth rate of the MTBC and 
persistence of viable organisms after the death of the host (Sterling et al., 2000; Weed & 
Baggenstoss, 1951). The mycobacteria are members of a taxonomic clade typified by 
organisms with a high percentage of guanidine and cytosine residues in their DNA. It is 
believed that the DNA of GC-rich bacteria is structurally more stable than that of other 
microbes because of the additional hydrogen bond cross-links between the DNA strands. 
The wealth of information on the genomics of M. tuberculosis strains present in the world 
today, coupled with our understanding of the co-evolution of M. tuberculosis with its human 
host, has attracted interest in determining the origins and timescale of this relationship. 
Relevant information can be obtained from archaeology, anthropology and 
palaeopathology, which provide details on past human populations, societies and the 
occurrence of infectious diseases. The relative robustness of M. tuberculosis biomarkers 
enables the well-established molecular methods used in diagnostic clinical microbiology to 
be applied, with appropriate modification, to the study of historical and archaeological 
remains. Originally the emphasis was on the detection and characterisation of M. tuberculosis 
ancient DNA (aDNA), as this enables the evolution of this group of pathogenic bacteria to 
be directly investigated by the detection and characterisation of their DNA (Fletcher et al., 
2003a, 2000b; Matheson et al. 2009; Zink et al., 2001). However, it was soon appreciated that 
the unique lipid biomarkers found in the MTBC, in addition to enabling the independent 
verification of aDNA studies (Donoghue et al., 1998, 2010a; Gernaey et al., 2001; Hershkovitz 
et al., 2008), have the potential to illuminate deep into human prehistory due to their 
particular stability (Gernaey & Minnikin, 2000; Redman et al., 2009).  
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2. Ancient DNA (aDNA) from the M. tuberculosis complex (MTBC): 
Background and basics  
2.1 DNA degradation and persistence  
Within living cells, DNA is subjected to enzymatic repair processes, but this ceases after 
death. Thereafter, host DNA is rapidly degraded by enzymes derived both from the host 
and the macro and microbial flora that form part of the natural decay process (Pääbo et al., 
2004). As a result of the cumulative changes over time (diagenesis) ancient DNA may 
develop hydrolytic and oxidative lesions. The breakdown of the N-glycosyl bond between 
the sugar and the base, in the presence of water, leads to hydrolytic cleavage and DNA 
fragmentation. Hydrolytic depurination causes a preferential loss of guanine and adenine, 
whereas the pyrimidines cytosine and thymine are 40-fold more susceptible to hydrolytic 
deaminisation (O'Rourke et al., 2000). Oxidative damage, especially to pyrimidines, can 
result in the formation of substances such as hydantoins, that block extension during PCR 
(Höss et al., 1996). DNA strands may also become chemically cross-linked due to Maillard 
products (Poinar et al., 1998), formed by condensation reactions between sugars and 
primary amino-groups in proteins and nucleic acids (Pääbo et al., 2004).  Local 
environmental conditions have a strong impact on the persistence of aDNA, such as the 
temperature, the pH at the site, the availability of water and oxygen and fluctuations of all 
these factors over time (Poinar, 2003). Indeed, these factors outweigh the impact of the 
chronological age of samples. For example, a 200C decrease in temperature reduces base 
degradation 10- to 25-fold (Höss et al., 1996). Mycobacterial DNA is more robust than that of 
mammals, but its persistence depends not only upon the local environmental conditions but 
also the nature of the infection at the time of death of its host. Therefore, M. tuberculosis 
aDNA is often highly localized and DNA extraction protocols may have to be optimized for 
specimens from different sites. 
2.2 Selection of specimens and sampling 
In the early days of palaeomicrobiology, the criteria drawn up by researchers working on 
ancient mammalian DNA were recommended. These included preliminary screening tests, 
such as using the degree of amino acid racemization (Poinar & Stankiewicz, 1999) or 
collagen yield (Götherström et al., 2002), as an indication of the extent of DNA preservation. 
However, it appears that these are not reliable indicators, even of mammalian aDNA 
(Fernañdez et al, 2009; Kaestle & Horsburgh, 2002). More recently, Ottoni et al. (2009) 
discovered that there was better recovery of aDNA from animal bones that showed 
evidence of cooking, concluding that parameters based on protein diagenesis are not always 
useful for predicting ancient DNA survival. Work on other microbial pathogens, such as 
Yersinia pestis – the cause of bubonic plague – demonstrate that the dental pulp cavity in 
sound adult teeth is an excellent source of aDNA (Drancourt et al., 1998). It is believed that 
adsorption to hydroxyapatite increases the stability of aDNA (Götherström et al., 2002; 
Tuross, 1994) and any microorganisms present in the blood will potentially be present 
(Donoghue, 2008a). 
For the examination of material for tuberculosis, the most common specimens available are 
bones. Most active cases of tuberculosis present as a lung disease, so ribs are a good source 
of M. tuberculosis DNA. Tuberculous lesions in the ribs arise by extension from spinal 
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lesions, from haematogenous spread from some remote soft tissue focus, or by direct spread 
from disease in the lungs, pleura, or chest wall lymphatic system (Mays et al., 2002). 
Initially, only bones with lesions were examined (Spigelman & Lemma, 1993), but it is now 
clear that in the majority of ancient cases of tuberculosis there are no lesions, but M. 
tuberculosis aDNA is present due to haematologous spread or by direct contact with infected 
tissue (Donoghue, 2011; Donoghue et al., 2011). Mummified tissue (Salo et al., 1994), skin 
(Faerman et al., 1997; Konomi et al., 2002), dental pulp (Faerman et al, 1997; Matheson et al, 
2009) and calcified pleura (Donoghue et al., 1998) have also yielded MTBC aDNA. 
Unfortunately, many published protocols based on human and animal aDNA research 
recommend that bones are pre-treated with bleach, ultraviolet light, or the outer bone 
surface is removed. The aim is thereby to remove surface contamination, but such 
procedures may inadvertently remove the very M. tuberculosis aDNA that is being sought 
(Donoghue, 2008a). 
2.3 MTBC aDNA extraction and detection by conventional PCR 
The amount of material examined by different investigators varies greatly (Donoghue et al., 
2009), but the subsequent extraction procedures follow a similar pattern. Mineralized tissue 
is powdered and demineralized, enzymes are used to remove proteins, the samples are 
disaggregated with agents such as phenol-chloroform or guanidium thiocyanate, and DNA 
is captured by silica, on to filters or membranes, or simply precipitated with isopropanol. 
Due to the persistent mycobacterial cell wall, robust techniques such as bead beating, freeze-
thaw cycles in liquid nitrogen, and incubation for longer time periods and at temperatures 
such as 560C are often used. The reagent N-phenacylthiazolium bromide may be used to 
overcome the problem of Maillard products and enable strand separation (Pääbo et al., 
2004). Reagents used for DNA capture may need modification to allow for DNA fragments 
that are <200 base pairs (bp) in length. In poorly preserved samples the fragment length 
may be less than 100 bp. Experience has shown that aDNA is unstable in aqueous solution 
so extraction preparations are best stored as dried silica or precipitates and only re-
constituted immediately prior to examination. Thereafter, the aDNA extracts should be 
aliquoted and stored at -800C, if possible, so the number of freeze-thaw cycles can be 
minimized. 
DNA amplification by PCR enables targeted and specific recovery of informative genetic 
loci. Amplification of MTBC aDNA is usually based on MTBC-specific regions of repetitive 
sequences in the genome of all members of the complex, such as IS6110 (Eisenach et al, 
1990). The sensitivity of conventional PCR can be increased by further amplification of the 
amplified PCR product via a nested reaction (Taylor et al., 1996). The primers devised by 
these two primer sets give rise to amplicons of 123 bp and 92 bp, respectively. IS6110 may 
have up to 24 copies/cell in M. tuberculosis (Tanaka et al., 2000), although a small percentage 
of strains have no copies at all and M. bovis strains have only a single copy per cell. The 
alternative specific PCR, based on IS1081 (Taylor et al., 2005), is preferable in most cases, as 
there are six copies/cell in each member of the MTBC so quantification is possible. 
Optimization of the PCR is necessary and modification of the PCR reaction mix is 
recommended for work with aDNA. Inclusion of stabilizers such as bovine serum albumin 
is often beneficial, probably due to a variety of effects such as masking non-specific binding 
sites, stabilizing DNA fragments and binding or otherwise inactivating co-purified PCR 
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inhibitors (Donoghue, 2008a). Hot-start PCR and excess enzyme can also drive the reaction 
and overcome residual inhibitors. Detection of amplicon has traditionally been based on 
agarose gel electrophoresis. Detection is also possible by hybridization of labelled amplicons 
to a membrane, using a dot block technique, for example. However, real-time PCR enables 
amplified product with an incorporated fluorescent marker or probe to be monitored 
directly via a computer screen and the methodology facilitates quantification. For the future, 
M. tuberculosis diagnostics is moving towards isothermal and array technology. Microarrays 
are not ideal for the direct detection of ancient M. tuberculosis in crude extracts, due to the 
extensive fragmentation of target sequences. However, the introduction of new platforms 
based on surface interactions and nanotechnology offer exciting possibilities for the future.  
2.4 Further developments in molecular diagnosis 
In recent years, the field of molecular diagnostics of tuberculosis has expanded rapidly and 
a wide variety of new techniques have been introduced, or are currently being validated for 
clinical use. This is beginning to have an impact on the specialized field of 
palaeomicrobiology (Section 3.2 below) and, no doubt, there will be many more studies in 
the future that will be based on such technology.  
2.4.1 Real-time PCR methods of MTBC aDNA detection and quantification 
Real-time PCR (RT-PCR) or, more correctly, quantitative PCR (qPCR) enables amplified 
product with an incorporated fluorescent marker or probe to be monitored directly via a 
computer screen. The underlying principle of non-specific double-stranded DNA binding 
dye chemistry is that fluorescent dyes such as SYBR Green intercalate with any double 
stranded DNA. This enables the progress of the amplification to be followed as it 
progresses, whereas conventional PCR relies upon the detection of amplicon once the 
reaction has completed. By use of standards and specific primers, the number of copies of 
amplicon or the absolute amount of DNA can be quantified. Normally a series of peaks are 
visible on the computer screen, so on completion a melt analysis is performed and the 
temperature at which strand separation occurs (Tm) is used to determine the targeted 
sequence. Greater clarity and specificity is conferred by the use of specific DNA probes, 
which incorporate a fluorescent reporter that is normally quenched (Nazarenko et al., 1997). 
The fluorescence is only released once the probe has bound to the specific target sequence. 
2.4.2 Other methods of MTBC aDNA detection in liquid systems 
Several isothermal target amplification methods, which avoid the use of a thermocycler 
machine, have been developed in the two past decades (Karami et al., 2011). Loop-mediated 
isothermal amplification (LAMP) is an isothermal molecular method of DNA amplification 
that has been successfully implemented in the detection of M. tuberculosis in clinical 
specimens (Notomi et al., 2000; Neonakis et al., 2011). The reaction is driven by outer 
primers leading to strand displacement DNA synthesis, production of a single-stranded 
template, further DNA synthesis initiated by additional primers, and hybridization to the 
other end of the target sequence to produce a loop. In subsequent cycles further strand 
displacement leads to multiple copies of the target sequence. LAMP has several advantages, 
such as rapidity, high sensitivity, ease of application and cost-effectiveness. 
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The change of scale by the use of nanoparticles reduces the need for multiple rounds of 
DNA amplification. For example, direct examination of clinical samples has successfully 
demonstrated M. tuberculosis DNA after an initial round of PCR, using a colorimetric 
method based on an M. tuberculosis probe linked to gold nanoparticles (Baptista et al., 2006). 
2.4.3 Detection of non-amplified DNA 
An alternative approach to conventional PCR is to directly detect non-amplified DNA by 
amplification of the detection system such as labelled probes (Bhatt et al., 1999).  However, 
the technology has now been developed to enable direct detection of sequences in non-
amplified genomic DNA by means of various sensors. In one example, a piezoelectric 
biosensor enables real-time and label-free detection of the hybridization reaction between an 
immobilized probe and the complementary sequence in solution. The DNA probe is 
immobilized on the sensing surface (10 MHz quartz crystals), while the complementary 
sequence is present in the genomic DNA, previously fragmented with restriction enzymes 
(Minunni et al., 2005). This approach has been developed for the detection of M. tuberculosis 
(Kaewphinit et al., 2010). Another specific DNA detection method uses fluorescent 
semiconductor quantum dots and magnetic beads for fast detection of mycobacteria without 
any DNA amplification. Two biotinylated oligonucleotide probes are used to recognize and 
detect specific complementary mycobacterial target DNA through a sandwich hybridization 
reaction. Quantum dots conjugated with streptavidin and specific probes are used to 
produce a fluorescent signal. Magnetic beads, conjugated with streptavidin and a genus-
specific probe are used to isolate and concentrate the DNA targets (Gazouli et al., 2010). 
Surface primer extension reactions may also be used to quantitatively detect unamplified, 
double-stranded genomic DNA (Martins et al., 2010). This methodology, by eliminating the 
need for pre-target labeling or amplification procedures, constitutes an alternative for the 
direct detection of genomic DNA from solution.  
2.5 Authentication and precautions  
Lists of precautions to take when working with mammalian aDNA have dominated 
palaeomicrobiology even though the recommendations may not be appropriate. For 
example, this is a summary of the "top ten list" drawn up by Poinar (2003):  
1. a physically isolated work area, preferably a separate building where no genetic work is 
carried out;  
2. PCR control amplifications, including non-template PCRs, multiple DNA and 
extraction controls;  
3. molecular behaviour i.e. an inverse relationship between amount of PCR amplicon (bp) 
and length of target sequence;  
4. quantification – the copy number of DNA should be assessed;  
5. reproducibility – results should be repeatable from both the same and different DNA 
extracts of a specimen; 
6. clone – direct sequencing should be confirmed by cloning amplicons and sequencing at 
least 10 clones to check for damage-induced errors and the ratio of endogenous to 
exogenous sequences;  
7. independent replication – preferably by the independent examination of separate 
samples of the same specimen in independent laboratories;  
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8. biochemical preservation – use indirect assessment of the extent of DNA preservation 
by assessing the amount of diagenic change in other biomolecules, such as amino acids 
or lipids;  
9. associated remains such as those of animals can be used to check for comparable aDNA 
survival to human DNA; 
10. phylogenetic sense – sequences should be compared with others in appropriate 
databases to ensure authenticity. 
Several of these recommendations have been accepted by palaeomicrobiologists, but a few 
are problematic: 
1. The suggestion of a separate building and clean rooms with filtered air supplies may be 
advisable for work on human aDNA, where every investigator is a potential source of 
contamination with modern DNA. However, the MTBC has no environmental 
reservoir, so provided that researchers do not suffer from tuberculosis it is quite 
possible to perform palaeomicrobiological research by following good microbiological 
practice, including plentiful negative controls and independent verification (Donoghue 
et al., 2009).  
2. Findings may not be reproducible because aDNA from tubercle bacilli will be localized. 
Even repeat samples from the same specimen may not yield a positive result in every 
case. Therefore, an additional criterion for work on a DNA of pathogenic 
microorganisms is proposed – that samples should be taken from sites appropriate to 
what is known of the natural history of the infection (Donoghue & Spigelman, 2006). 
3. There is no evidence that cloning is necessary for verification of mycobacterial aDNA. 
Indeed, the opposite is true as work on Mycobacterium leprae (Taylor et al., 2006) showed 
that cloning gave no added value to data obtained by direct sequencing, but did 
introduce some errors, which were ascribed to Taq polymerase error and slipped strand 
mispairing. Similar conclusions have been reached in a recent study of mammalian 
aDNA (Winters et al., 2010). 
4. Independent replication of aDNA may give discordant results due to localization of 
pathogen biomarkers within samples (see point (5) above). MTBC-specific lipid 
biomarkers may be more sensitive and can verify aDNA data without the need for 
amplification (Section 4 below) even though determined sceptics (Wilbur et al., 2009) 
may ignore this (Donoghue et al., 2009). 
5. Comparison with different host biomolecular markers is discussed above (Section 2.2) 
and the conclusion is that aDNA can be found even in samples where other 
biomolecules are damaged. 
6. Comparison with the recovery of aDNA from associated faunal remains is 
inappropriate for MTBC aDNA for at least two reasons. First, mycobacterial DNA 
appears to be more robust than mammalian DNA (Section 2.1). In addition, faunal 
remains are often a poorer source of aDNA than associated human remains (Mays et al, 
2001), possibly due to treatment of carcasses after death and the absence of burial 
(Taylor et al., 2010).  
3. Palaeomicrobiology of tuberculosis  
3.1 Early studies 1993–2002 and initial conclusions   
The earliest molecular studies on aDNA of the MTBC demonstrated proof of principle, but 
also answered historical questions about the occurrence of tuberculosis in the pre-colonial 
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Far East (Spigelman & Lemma, 1993) and whether tuberculosis occurred in the Americas 
before Columbus (Salo et al., 1994). During the first decade of such research it was 
demonstrated that MTBC aDNA could be found in bone and mummified tissue, from body 
sites in specimens without lesions and of a broad age range, from locations around the 
world (Donoghue, 2011). Additional methods of examination included pathology, 
microscopy and radiology. Authentication was provided by the direct detection of MTBC-
specific cell wall lipid markers (Donoghue et al., 1998, Gernaey et al., 2001). Use of 
additional PCR target sites, including rpoB, mtp40, oxyR and spoligotyping – which uses a 
dot-blot method based on the MTBC Direct Repeat (DR) region (Kamerbeek et al., 1997), 
enabled confirmation of the principal human pathogen M. tuberculosis sensu stricto (Taylor et 
al., 1999). The oldest confirmed case of tuberculosis was reported in a Pleistocene bison 
(17,870 BP) from the Natural Trap Cave, Wyoming, USA. A metacarpal showed suggestive 
pathology and spoligotyping indicated that the infecting organism was a member of the 
MTBC, but the species was not confirmed at the time (Rothschild et al., 2001). 
3.2 Recent findings and increased understanding 
The increased understanding arising from total genome sequencing of M. tuberculosis (Cole 
et al., 1998) led to an appreciation that this group of organisms exhibits sequential deletions 
that can be used to distinguish between strains and lineages. Therefore, molecular typing 
protocols were developed based on a combination of synonymous single nucleotide 
polymorphisms (SNPs) in the katG codon 463 (katG463), gyrA codon 95 (gyrA95) and deletions 
(Brosch et al., 2002). The TbD1 deletion was identified as specific to the human pathogen M. 
tuberculosis and a significant marker of "ancestral" and "modern" strains. Therefore, both 
SNP typing and deletion analysis have been incorporated into MTBC aDNA studies, 
provided that the DNA preservation was sufficiently good for such single-copy markers to 
be amplified and detected. 
The next decade included population studies and early epidemiological findings. A well-
documented group of over 200 naturally mummified individuals from the 18th century was 
discovered in a church crypt in Vác, Hungary (Fletcher et al., 2003a). DNA preservation was 
particularly good and there was a high level of both active and presumed latent infections 
(Donoghue et al., 2011). It was possible to perform molecular fingerprinting and genotyping 
based on SNPs and to identify the M. tuberculosis aDNA as of "modern" strains. These 
techniques were used to demonstrate that in a small family group each person was infected 
with a different M. tuberculosis strain (Fletcher et al., 2003b). Interim epidemiological data 
have also been obtained from an on-going study of early Christian Nubians (550–750 and 
750–1500 CE) and it is clear that tuberculosis was widespread, although there are no 
contemporaneous records and the DNA preservation is much less good (Donoghue, 2008b; 
Spigelman et al., 2005). Meanwhile, Zink, Nerlich and colleagues have produced a series of 
papers from a long-term study of burials in Thebes-West in ancient Egypt (Zink & Nerlich, 
2004; Zink et al., 2003a, 2003b, 2004), spanning the pre-Dynastic period (5500–3100 BCE) to 
the New Kingdom (1550–1070 BCE). Molecular typing and spoligotyping indicated human 
M. tuberculosis and there was also evidence of another member of the MTBC, Mycobacterium 
africanum. However, no M. bovis was found. Indeed, there has only been one reported case of 
human tuberculosis associated with M. bovis aDNA (Taylor et al., 2007). This was found in a 
small group of pastoralists in south Siberia, dating from approximately 1761 to 2199 years 
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BP, placing the remains within the Iron Age period. Further work on the same specimens 
used qPCR to detect, quantify and characterize the M. bovis DNA (Murphy et al., 2009).  
The use of qPCR with specific fluorescent reporters should enable the detection of highly 
fragmented aDNA. This was demonstrated by the detection of a 63 bp IS6110 target 
sequence specific for the MTBC in a pre-Hispanic (900–1100 CE) adult from the north coast 
of Peru (Klaus et al., 2010). Both conventional and qPCR were used to examine skeletal 
material from western Hungary with palaeopathology suggestive of tuberculosis (Évinger et 
al., 2011). Samples were dated from 800–1200 CE and the qPCR with a specific 75 bp IS6110 
target sequence was positive in six cases including two from the 9th century, whereas 
conventional PCR was negative. However, conventional PCR with a 113 bp target sequence 
for IS1081 was positive in two of these cases plus one other, but a qPCR probe with a 72 bp 
target sequence was negative, thus demonstrating the lack of consistency when seeking 
aDNA from microbial pathogens in human tissue.  
3.3 Association of tuberculosis with other diseases 
3.3.1 Co-infections 
There has been no systemic examination of archaeological or historical material for co-
infections, but our current understanding is that a pre-existing infection can increase 
susceptibility to another. A recent historical example is the influenza pandemic of 1918 
where a major cause of death is believed to have been secondary bacterial pneumonia 
(Morens et al., 2008). It is very likely that additional examples will be found. 
For example, parallel developments in the molecular detection of M. tuberculosis and M. 
leprae aDNA enabled co-infected individuals to be identified. These were cases of 
lepromatous leprosy with very typical palaeopathology, who were subsequently discovered 
to have systemic M. tuberculosis aDNA in their skeletal remains (Donoghue et al., 2005). An 
extensive literature search revealed that such co-infections had been reported in historical 
times prior to the introduction of chemotherapy; the findings led to a hypothesis that 
tuberculosis might have been a major factor in the elimination of leprosy from Western 
Europe. 
An example of an association of tuberculosis with a parasite infection comes from pre-
colonial northern Peru, where Chaga's disease, caused by the protozoan parasite 
Trypanosoma cruzii, was widespread (Aufderheide et al., 2004). Palaeopathology and aDNA 
analysis demonstrated both Chaga's disease and tuberculosis in the population and one 12 
year-old girl from 910-935 BP was shown to have a co-infection (Arriaza et al., 2008). 
Another such association between tuberculosis and Leishmania spp. infection, possibly also 
linked to nutritional stress, was reported in preliminary data from early Christian Nubia 
(Spigelman et al., 2005).  
3.3.2 Co-morbidity 
There are many examples of increased susceptibility to infection associated with poor 
nutrition, a compromised immune system e.g. in neonates or the elderly, physical or mental 
stress due to wars and relocation, and underlying other medical conditions. An example of 
an association of tuberculosis with reduced lung function due to a massive vertebral 
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deformity, probably developmental, was described by Kustár et al. (2011) in an 18th century 
mummified lung from Vác, Hungary. Another individual from the same population, a child 
aged 1.5 – 2.5 years, showed numerous bony lesions throughout the body (Spigelman et al., 
2006). A differential diagnosis, based upon the palaeopathology led to the conclusion that 
this infant suffered from Langerhans' cell histiocytosis (LCH), also referred to as 
histiocytosis-X. The aetiology and pathogenesis of LCH are still unknown but it is now 
thought to be a neoplasm, so the finding of tuberculosis in this child is not surprising. The 
child would have a repressed immune system, due to marrow replacement by the malignant 
cells, and thus be vulnerable to tuberculosis, which was widespread in this community. 
3.4 MTBC lineages, evolution and timescale 
The association of M. tuberculosis lineage with that of their human host has been 
convincingly illustrated in modern populations (Section 1). There is low DNA sequence 
variation in the MTBC and little, if any, horizontal gene exchange, which prevents 
reacquisition of genomic regions that have been lost. Therefore, deletions and functionally 
neutral SNPs are ideal markers for inferring deep phylogenies (Donoghue, 2009). The SNPs 
in the katG codon 463 (katG463), gyrA codon 95 (gyrA95) and the TbD1 deletion (Brosch et al., 
2002) enable differentiation of three principal genetic groups within the MTBC. It is believed 
that these organisms have undergone an evolutionary bottleneck, associated with the 
adoption of a parasitic lifestyle. Thereafter, both host and pathogen have undergone clonal 
expansion. The timescale during which this has occurred is of interest, not least because of 
the realization that the evolution of the MTBC appears to be increasing exponentially today 
and the underlying factors need to be understood.  
Although tuberculosis is still the greatest single cause of death caused by a single microbial 
pathogen, the high proportion of infected persons with latent infection indicates that host 
and pathogen have co-existed for a considerable length of time (Donoghue, 2009; Rustad et 
al., 2009). It is believed that the emergence of human pathogens is related to population 
density and tuberculosis has long been recognized as associated with the development of 
agriculture and animal domestication during the Neolithic transition. Palaeopathological 
data alone cannot distinguish between M. tuberculosis and M. bovis infection, and the earlier 
belief that human tuberculosis was derived from the animal disease has proved difficult to 
shift. However, palaeomicrobiology provides convincing evidence that M. bovis is rare in 
past human populations. Direct evidence of infection with human lineages was provided 
from ancient Egypt by genotyping and deletion analysis (Zink & Nerlich, 2004, Zink et al., 
2003a) and spoligotyping (Zink et al., 2003b). Demonstration of the oldest infection with 
human lineages of the MTBC (Hershkovitz et al., 2008) was based on five different target 
sequences, and was confirmed by direct detection of M. tuberculosis-specific mycolic acid 
markers (see Section 4.2 below). The population was from a Pre-Pottery Neolithic site in the 
Eastern Mediterranean, dated around 9000 years ago, with plentiful evidence of animal 
domestication. It is therefore of special interest that the M. tuberculosis lineage is of a TbD1-
deleted strain. 
Ancestral sequence inference is a process used in bioinformatics to estimate the rate of 
evolutionary change under different scenarios. Combination with the direct evidence 
obtained from palaeomicrobiology, enables confirmation of the presence of particular M. 
tuberculosis lineages in the past, which can strengthen and inform existing models. This has 
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led to a significant extension of the timescale for the evolution of the MTBC. For example, 
when Brosch et al. (2002) first published their evolutionary model, it was noted that the 18th 
century Vác mummies were of M. tuberculosis of principal genetic groups 2 and 3, thus 
proving that these had not evolved during recent times. Six years later it was appreciated 
that the "modern" TbD1-deleted lineages existed 9000 years ago (Hershkovitz et al., 2008). It 
appears likely that further extension of the timescale will require the introduction of the 
more sensitive immobilized DNA technologies to enable detection of the highly fragmented 
material in such ancient samples.  
4. Lipid biomarkers for the M. tuberculosis complex (MTBC)  
4.1 Established lipid biomarkers for MTBC 
The cell envelope of M. tuberculosis is based on complex macromolecules linked to produce a 
mycoloyl arabinogalactan-peptidoglycan organelle (Minnikin 1982; Barry et al., 2007). This 
organelle is the foundation for a characteristic mycobacterial outer membrane based on 
covalently bound mycolic acids, interacting with a range of unusual free lipids (Minnikin, 
1982; Minnikin et al., 2002). This outer membrane has now been visualized directly 
(Hoffmann et al., 2008; Zuber et al., 2008) and given the label “mycomembrane”. Mycolic 
acids are, therefore, an integral part of mycobacterial cell envelopes, with proven biomarker 
value, both in classification and identification, due to variations in the individual mycolate 
types expressed (Butler & Guthertz, 2001; Dobson et al., 1985). The mycolic acids produced 
by M. tuberculosis are composed of five principal types, as illustrated in Fig. 1A, each type 
having a range of homologues with different chain lengths (Minnikin, 1982; Minnikin & 
Polgar, 1967a, 1967b; Watanabe et al., 2001, 2002). This general mycolate fingerprint is 
shared by M. tuberculosis and other members of the MTBC, whose best-studied members 
include M. bovis, M. africanum and Mycobacterium microti. MTBC mycolic acids are relatively 
stable biomarkers, which have been detected in archaeological material up to 9,000 years old 
(Hershkovitz et al., 2008). The use of mycolate biomarkers in the identification of 
tuberculosis depends on the clear recognition of profiles characteristic of the MTBC; this will 
be discussed in detail below (Sections 4.2 & 4.3). 
The so-called “free” lipids, which associate with the “polysaccharide-bound” mycolic acids 
to form the outer myco-membrane (Minnikin, 1982; Minnikin et al., 2002), are also a source 
of diagnostic lipid biomarkers. The mycocerosic and mycolipenic acids (Fig. 1B) are the best-
studied examples, the former being components of phthiocerol dimycocerosate waxes and 
the latter being part of pentaacyl trehalose glycolipids (Minnikin et al., 1983, 1985a, 1985b, 
2002). Mycocerosic acids are found in a limited number of mycobacterial species, including 
Mycobacterium kansasii, M. leprae and Mycobacterium haemophilum in addition to members of 
the MTBC; Mycobacterium marinum and Mycobacterium ulcerans have closely related acids 
(Minnikin et al., 2002). The distribution of the different mycocerosate types has been defined 
(Daffé & Lanéelle, 1988; Minnikin et al., 1985a; Minnikin et al., 1993a), with MTBC having a 
characteristic pattern composed of mainly C29, C30 and C32 components (Fig. 1B). In contrast, 
only a single C27 mycolipenate (Fig. 1B) is usually encountered and principally in only M. 
tuberculosis. The value of mycocerosic and mycolipenic acid lipid biomarkers in the 
diagnosis of ancient tuberculosis has been investigated by Redman et al. (2009). An 
important aspect of identifying lipid biomarkers in archaeological samples is that such 
lipids are being increasingly implicated as virulence factors in the pathogenesis of M. 
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tuberculosis (Gordon et al. 2009; Neyrolles & Guilhot, 2011); this is a further avenue for 
research into the evolution of the host/pathogen relationship. 
 
 
Fig. 1. Structures of selected lipid biomarkers for M. tuberculosis. A. The main components of 
each mycolic acid class are shown; each class comprises a limited range of homologous 
components with different chain lengths. B. Mycolipenic and mycocerosic acids; for each 
component, the ions (m/z) monitored on negative ion-chemical ionization gas 
chromatography-mass spectrometry (NICI-GCMS) of pentafluorobenzyl esters of these 
acids are given. 
4.2 HPLC recognition of MTBC mycolic acid patterns in archaeological samples 
The mycolic acids from M. tuberculosis (Fig. 1A) comprise three principal classes, -, 
methoxy- and keto-, which can be separated from each other by simple so-called “normal 
phase” chromatography. Such separations are readily achieved by thin-layer 
chromatography (Dobson et al., 1985; Minnikin, 1993) or by high performance liquid 
chromatography (HPLC) on silica gel media (Minnikin, 1993; Qureshi et al., 1978; Steck et 
al., 1978). Normal phase profiles of total mycolates, simply showing -, methoxy- and 
ketomycolate classes, are not diagnostic for the MTBC, as they are shared with a range of 
other mycobacterial species (Dobson et al., 1985; Minnikin, 1982; Watanabe et al., 2001, 
2002). “Reverse phase” HPLC separates mycolates both according to chain length and 
polarity (Minnikin, 1993; Qureshi et al., 1978; Steck et al., 1978), and a characteristic “tight 
envelope” of peaks is produced by members of the MTBC (Donoghue et al., 2010a; Gernaey 
et al., 1998, 2001; Hershkovitz et al., 2008). This diagnostic profile has been found to be 
sufficient for the routine diagnosis of modern clinical tuberculosis, using computerized 
comparison to an internal standard (Butler & Guthertz, 2001). It is conceivable, however, 
that a combination of various factors could produce an envelope of peaks mimicking that 
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characteristic of tuberculosis. Extra dimensions of information are readily available if 
reverse phase HPLC is carried out on the individual -, methoxy- and keto-mycolate classes 
(Donoghue et al., 2010a; Gernaey et al., 1998, 2001; Hershkovitz et al., 2008; Minnikin et al., 
1993b). As shown in Fig. 1A, methoxy- and keto-mycolates have sub-classes depending on 
the presence of the alternative cis-cyclopropane or methyl branched trans-cyclopropane 
moieties; these sub-classes are not readily separable by normal phase chromatography 
(Donoghue et al., 2010a; Gernaey et al., 1998, 2001; Hershkovitz et al., 2008; Watanabe et al., 
2001).  
The first detection of mycolic acid biomarkers in archaeological skeletal material was 
performed in studies by Gernaey et al., (1998, 1999, 2001, 2002) and extended to calcified 
pleura (Donoghue et al., 1998). The sensitive HPLC analysis used mycolate methylanthryl 
esters, previously developed to diagnose modern tuberculosis in human sputum (Minnikin 
et al., 1993b). The derivatized mycolic acids were isolated by reverse phase HPLC and the 
total mycolate fraction was collected and analyzed by normal phase HPLC to separate the -, 
methoxy- and ketomycolate classes. These individual mycolate classes were then resolved 
into envelopes of peaks diagnostic for MTBC by further reverse phase HPLC. The value of 
this effective sequential protocol will be demonstrated below (Fig. 2) for a more recent 
example (Hershkovitz et al., 2008). The archaeological material investigated by Gernaey et 
al. (1998, 1999, 2002) was a collection of 19th century skeletons excavated from the site of the 
old Newcastle upon Tyne Infirmary, UK; there was a good correlation with burial records. 
The power of combining aDNA and mycolate analyses was first demonstrated for 1,400 year 
old calcified pleura from Karkur in the Negev desert (Donoghue et al., 1998, 2004). In 
another combined study, Gernaey et al. (2001) showed that mediaeval skeletons from 1,000 
years ago in Addingham, Yorkshire, UK had evidence of tuberculosis. These particular 
landmark samples were in fact the first in which mycolic acid, or any other, lipid biomarkers 
had been seen. Some of these early investigations have been reviewed by Gernaey & 
Minnikin (2000). 
The methylanthryl derivatives used in the above pioneering studies were not ideal as 
their relative instability required that the sequential HPLC analyses must be done quickly, 
with minimum storage. A systematic exploration of derivatization protocols resulted in 
the selection of pentafluorobenzyl (PFB) mycolic acid esters, further esterified with 
pyrenebutyric acid (PBA). Ample justification of this selection was provided by 
confirmation of the oldest proven case of tuberculosis in ribs from a woman and child 
from a neolithic pre-pottery settlement at Atlit-Yam in the Eastern Mediterranean, dated 
at around 9,000 BP (Hershkovitz et al., 2008). The mycolic acid profiles for these extracts 
are shown in Fig. 2. The immaculate preservation of the mycolic acid biomarkers is 
illustrated by the remarkable similarity of the total mycolate profiles from the three 
skeletal extracts with that from authentic M. tuberculosis (Fig 2A). It must be remembered 
that the profiles in Fig. 2A represent a conglomerate of all five classes shown in Fig. 1, but 
it is a characteristic of MTBC mycolates that they cluster together to give a “tight 
envelope” of distinct peaks. Subjecting the collected total mycolates to normal phase 
HPLC (Fig. 2B) shows the proportions of the -, methoxy- and ketomycolate classes but 
the methoxy- and keto- components having either cis- or trans- cyclopropane rings (Fig. 
1A) are not separated.  
 
Understanding Tuberculosis – Deciphering the Secret Life of the Bacilli 
 
16
Reverse phase HPLC of the collected -mycolates (Fig. 3A) gives a profile of simple 
regularly spaced peaks corresponding to the single class of -mycolates with two cis-
cyclopropane rings; the main C80 component corresponds to the structure shown in Fig. 1A. 
The reverse phase HPLC profiles for the methoxymycolates from M. tuberculosis and the 
Atlit-Yam skeletons (Fig. 3B) are particularly informative. The main C85 component is the 
cis-methoxymycolate shown in Fig. 1A and the minor C88 component (Fig. 3B) is the 
principal trans-methoxymycolate given in Fig. 1A. Again the excellent correlation between 
the methoxymycolate profiles from standard M. tuberculosis and the archaeological samples 
illustrates the remarkable preservation of these samples. The main C87 trans-ketomycolate 
(Fig. 1A) dominates the reverse phase HPLC of the ketomycolates (Fig. 3C); the C86 cis-
ketomycolate (Fig. 1A) is a very minor component (Fig. 3C). The particular mosaic of 
patterns, shown in Figs. 2 and 3, appears to be very characteristic for M. tuberculosis sensu 
stricto. In continuing unpublished studies, it is becoming apparent that the patterns recorded 
for M. bovis may possibly be distinguished by different proportions of the cis- and trans- 
methoxy- and ketomycolates; this is in accord with detailed structural studies (Watanabe et 
al., 2001, 2002). 
 
Fig. 2. HPLC of pyrenebutyric acid (PBA) esters of pentafluorobenzyl (PFB) esters of mycolic 
acids extracted from skeletons from Atlit-Yam and standard M. tuberculosis. Reproduced 
from Hershkovitz et al. (2008). A. Reverse phase HPLC of total mycolates. B. Normal phase 
HPLC of total mycolates, collected from 2A. 
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In addition to providing diagnostic profiles, HPLC allows quantitative data to be recorded. 
In particular, the relative proportions of the -, methoxy- and ketomycolate types (Fig. 1A) 
are readily determined, as exemplified (Table 1) for the mycolates from Atlit-Yam 
(Hershkovitz et al., 2008). The -mycolates contribute about half the mixture, with one 
quarter to one third being methoxymycolates and one tenth to one fifth being ketomycolates 
(Table 1). This good correlation of mycolate class proportions in the skeletal extracts with 
the M. tuberculosis standard is a clear indicator of good sample preservation. As will be 
discussed below for another study (Minnikin et al., 2011), degraded samples appear to lose 
their methoxy- and ketomycolates, particularly the latter. It is also possible to estimate the  
 
Fig. 3. HPLC of pyrenebutyric acid (PBA) esters of pentafluorobenzyl (PFB) esters of mycolic 
acids extracted from skeletons from Atlit-Yam and standard M. tuberculosis. Reproduced 
from Hershkovitz et al. (2008). A, B, & C. Reverse phase HPLC of -mycolate, 
methoxymycolate and ketomycolate classes, respectively, collected from the normal phase 
separation illustrated in Fig. 2B. 
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absolute amounts of mycolic acids present, as shown (Table 2) for the Atlit-Yam extracts 
(Hershkovitz et al., 2008). The amount of mycolate in the 635 mg Woman left rib (12.80 µg) is 
most exceptional, equating to an almost weighable and visible one hundredth of a 
milligram! This suggests a very heavy tuberculosis infection in the bone from the Woman, as 
compared to that from the Infant, which is 168 times less; such snapshot comparisons are 
not statistically valid, however, as it would be necessary to examine a comparable range of 
bones from each individual several times over.  
Mycolate Woman’s left rib 
Woman’s right 
rib Infant’s rib M. tb. standard 
Alpha- 56.3 52.65 53.2 48.2 
Methoxy- 25.2 34.50 32.2 37.4 
Keto- 18.5 12.85 14.6 14.4 
Table 1. Percentage ratios of alpha-, methoxy- and ketomycolates in skeletons from Atlit-
Yam. Reproduced from Hershkovitz et al. (2008). 
Bone sample Bone mass Mycolate in bone Mycolate/bone load 
Woman’s left rib 635 mg 12.80 µg 20.14 µg/g 
Woman’s right rib 483 mg 1.697 µg 3.51 µg/g 
Infant’s rib 589 mg 0.073 µg 0.12 µg/g 
Table 2. Absolute amounts of mycolic acids in skeletons from Atlit-Yam. Reproduced from 
Hershkovitz et al. (2008). 
Another example of good mycolic acid biomarker preservation is provided by the 
interesting case of Dr. Granville’s mummy (Donoghue et al., 2010a). The subject is the lady 
Irtyersenu of the 26th Dynasty (ca. 2600 BP) from the necropolis of Thebes. Although aDNA 
from the MTBC was detected, the material was very difficult to work with, possibly due to 
the embalming method, which appears to have been unusual. In contrast, the mycolic acid 
HPLC traces were almost as pristine as those from the Atlit-Yam samples (Figs. 2 and 3) 
(Hershkovitz et al., 2008). These results, in conjunction with aDNA detection, clearly 
confirmed tuberculosis infection, which may have made a major contribution to the death of 
Irtyersenu (Donoghue et al., 2010a). However, pristine mycolic acid HPLC traces are by no 
means the norm in archaeological samples from subjects suspected to have suffered from 
tuberculosis. In a study aimed to test the possibility of detecting lipid biomarkers in 
archaeological material, after aDNA has been extracted and analyzed, a range of samples 
from subjects suspected to have been infected with tuberculosis, leprosy or both were 
investigated (Minnikin et al., 2011). Evidence of mycolic acids was found in all samples, 
thereby proving that it was possible to isolate lipid biomarkers from aDNA analysis 
residues; the hydrophobic lipids were not extracted by the aqueous media used to release 
aDNA. The total mycolate reverse phase HPLC profiles were complex and the normal phase 
HPLC traces all had -mycolates but the methoxy- and ketomycolates were variable to non-
existent, excepting two cases where good clear peaks for ketomycolates were recorded. The 
results in this paper are too complex to summarize concisely. For the 12 cases, suffice it to 
say that five diagnoses agreed with the aDNA (three tuberculosis, two leprosy), five cases 
did not correlate clearly and for two extracts the mycolic acids were so degraded that it was 
impossible to support positive aDNA diagnoses. This instructive study suggests that it is 
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important to obtain as much biomarker information as possible, particularly where mixed 
tuberculosis/leprosy cases are a probability. For one particular 7th century skeleton from the 
Avar period in Hungary, it was possible to recognise mycolic and mycocerosic acids from 
both M. tuberculosis and M. leprae (Lee et al., 2012). The quantitative data suggested a 
predominance of tuberculosis over leprosy in contrast to the bone pathology which 
indicated only leprosy. The presence of mycolic acids supported an aDNA diagnosis of 
leprosy in a 1st to 4th century CE skeleton from Uzbekistan (Taylor et al., 2009).  
4.3 Mass spectrometry in detection of mycolic acid biomarkers for ancient 
tuberculosis 
Mass spectrometry was a key technique in establishing the essential structures (Fig. 1A) of 
the mycolic acids of M. tuberculosis for the first time (Minnikin & Polgar, 1967a, 1967b; 
Minnikin, 1982), providing accurate molecular weights. Initially, the individual -, methoxy- 
and ketomycolates were analysed separately by the pioneering but rather cumbersome high 
energy Electron Ionisation (EI) mode of mass spectrometry, which produces complex 
spectra with characteristic fragmentation patterns. Matrix Assisted Laser Desorption 
Ionisation Time of Flight (MALDI-TOF) mass spectrometry is a convenient lower energy 
technique that often gives peaks corresponding to molecular weights augmented by 
ubiquitous sodium ions (M + Na+). MALDI-TOF mass spectrometry was used to 
characterize a range of individual mycolate types in a comprehensive study (Watanabe et 
al., 2001) aimed at determining the precise location of functional groups in mycolic acids 
(Watanabe et al., 2002). In a parallel study, Laval et al. (2001) demonstrated that MALDI-
TOF mass spectrometry of mycolic acid methyl esters can be used to provide a characteristic 
profile of total mycolic acid composition. 
Based on the previous study by Laval et al. (2001), Mark et al. (2010) used MALDI-TOF mass 
spectrometry to search for tuberculosis mycolic acids in ancient bones. However, the 
profiles recorded by Mark et al. (2010) did not resemble those expected for mycolic acids, so 
a response to this paper was published (Minnikin et al., 2010). This response suggested 
guidelines for the satisfactory recognition of mycolic acid profiles diagnostic for M. 
tuberculosis. Remarkably, the original clearly inadequate conclusions were vigorously 
defended by Mark et al. (2011), without providing any new convincing data. It is most 
important, therefore, to demonstrate beyond doubt that the data provided by Mark et al. 
(2010, 2011) are not evidence for tuberculosis infection in any of the analyzed archaeological 
samples, whatsoever; the problems raised by these papers are considered in detail below. 
The paper of Minnikin et al. (2010) provided a considered in-depth constructive analysis of 
the inadequacies of the data shown in Mark et al. (2010), so these criticisms will not be 
repeated in detail. The essence of the problems in both papers published by Mark et al. 
(2010, 2011) is exemplified by the data shown in Figs. 4 and 5. The profile shown in Fig. 4A 
(Mark et al., 2010) is suggested to be that of standard M. tuberculosis mycolic acids, but it 
only shows a series of regularly spaced peaks, more suggestive of polymeric material than 
distinct components of the family of mycolic acids shown in Fig. 1A. Similarly, the profile 
for an extract of a skeleton from Sükösd-Ságod (grave 19) (Fig. 4B) again showed a regular 
series of peaks, with limited correspondence between the data in Figs. 4A and 4B. The 
different classes of mycolic acids (Fig. 1A) occur naturally as groups of peaks with one or 
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two major components accompanied by several minor homologues (Minnikin & Polgar, 
1967a, 1967b; Minnikin, 1982; Watanabe et al., 2001, 2002). Mycolic acids (Fig. 1A) are long-
chain fatty acids, with series of homologues whose biosynthetic pathways dictate a general 
spacing of two methylene groups (-CH2.CH2-) amounting to 28 atomic mass units (amu). It 
is, therefore, totally impossible that the patterns presented in Figs. 4A and 4B, with spacings 
of 44 amu, can be assigned to homologous series of mycolic acids. Mark et al. (2010) 
hypothesize that the ion spacings are a result of carbon dioxide (44 amu) loss but this does 
not correlate with any known properties or published behaviour of any mycolic acids or, 
indeed, any other fatty acids. As suggested previously (Minnikin et al., 2010), an alternative 
explanation for the regular 44 amu spacing of the components is that the peaks are derived 
from a material incorporating polyethylene glycol repeating units. These polymeric 
polyethylene glycol-based preparations are in widespread industrial use and the risk of 
their appearance in mass spectra is well-known, as emphasized by, for example, by Keller et 
al. (2008) and Schiller et al. (2004), the latter reproducing a representative MALDI-TOF mass 
spectrum. Another general point, which comprehensively disqualifies the profiles in Figs. 
4A and 4B, is the undisputed fact that mycolic acids do not have recorded molecular 
weights greater than 1350 amu (Laval et al., 2001; Watanabe et al., 2001, 2002) so the 
presence of alien substances is suspected. As noted above, these and other criticisms have 
been thoroughly aired by Minnikin et al. (2010) in a constructive attempt to establish reliable 
guidelines for the recognition of mycolic biomarkers in the diagnosis of ancient tuberculosis. 
 
Fig. 4. MALDI-TOF mass spectra, reproduced with permission from Mark et al. (2010). A. 
Mycolic acid standard; Fig. 2 of Mark et al. (2010). B. Extract of bone sample from Sükösd-
Ságod grave 19; Fig. 3A of Mark et al. (2010). 
However, Mark et al. (2011) declined to acknowledge the obvious and indisputable errors 
and deficiencies, raised by Minnikin et al. (2010), in the original paper of Mark et al. (2010). 
In a most unsatisfactory manner, Mark et al. (2011) were able to submit their response on 
17th December 2009, precisely one calendar month after the receipt of Minnikin et al. (2010) 
on 19th November 2009. This indisputably proves that unauthorized privileged information 
had been provided to Mark et al. (2011), well in advance of the due confidential reviewing 
process for the manuscript of Minnikin et al. (2010). Disregarding the deficiencies and 
practises in the publication process, attention must be focussed on the data and arguments 
advanced in the publication of Mark et al. (2011). As shown in Fig. 5A, the mass spectrum of 
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an authentic sample of M. tuberculosis mycolic acids was recorded (Mark et al. 2011) and this 
is very different from that shown in Fig. 4A, for supposedly the same material (Mark et al., 
2010). The mass spectrum of an extract from the skeleton from Sükösd-Ságod (grave 19) (Fig. 
5B) is again clearly distinct from the spectrum recorded for the same bones (Fig 4B) by Mark 
et al. (2010). More disturbingly, the supposedly positive spectrum recorded in Fig. 5B has 
little resemblance to that of the authentic standard (Fig. 5A). The most significant, but 
unknown, peak at m/z 1361.1 (Fig 5B) is clearly too large in mass to be a mycolic acid, as the  
 
Fig. 5. MALDI-TOF mass spectra, reproduced with permission from Mark et al. (2011). A. 
Mycolic acid standard, provided by David E. Minnikin (University of Birmingham, UK); 
Fig. 3B of Mark et al. (2011). Peaks at m/z 1160 and 1188 are C78 and C80  -mycolates, m/z 
1274 is C85 cis-methoxymycolate and m/z 1302 is C87 trans-ketomycolates (see Minnikin et al., 
2010 for a spectrum of the same sample). B. Extract of bone sample from Sükösd-Ságod 
grave 19; Fig. 4A of Mark et al. (2011). 
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highest component in the authentic standard is centred around m/z 1330 (Fig. 5A). In three 
other supposedly positive mass spectra, reported by Mark et al. (2011), the unknown, non-
mycolic acid, peak at m/z 1361 is the main component. Incontrovertibly, the spectrum of the 
extract of the skeleton from Sükösd-Ságod (grave 19), shown in Fig. 5B, does not provide 
any evidence for the presence of tuberculosis, providing a double negative diagnosis for the 
same skeleton as the profile in Fig. 4B was also woefully inadequate. 
The science displayed by Mark et al. (2010) has been thoroughly discussed by Minnikin et al. 
(2010) but it is also necessary, for the record, to draw critical attention to claims made in 
Mark et al. (2011). In this paper, there is an extensive discussion (page 1112, section 3) about 
whether it is likely to be possible to detect unmodified mycolic acids in archaeological 
samples. The key statement is “it would be very surprising if the mass spectra of ancient 
mycolic acid biomarkers were exactly the same as those of recent standards and clinical 
samples”; presumably this is aimed at providing some justification for claiming that the 
spectra exemplified in Figs. 4B and 5B (this Chapter) represent naturally modified mycolic 
acids. This argument is taken further in the statement “the identification of ancient mycolic 
acids and their metabolites could only be carried out with accurate and systematic chemical 
modelling of the mycolic acid post-mortem diagenesis”. The implication of this statement is 
that diagenetic studies are a prerequisite but there are no suggestions about how this might 
be done. One way to approach this is to make extracts of suspected infected archaeological 
material and examine them by established objective protocols, such as HPLC, to determine 
if mycolic acids or their degradation products are recognisable. This is precisely the 
approach taken by Gernaey et al. (2001), Hershkovitz et al. (2008), Donoghue et al. (2010) 
and Minnikin et al. (2011); in the latter publication substantial degradation of mycolic acids 
is clearly recorded but in the others clearly recognisable mycolic acid patterns are 
documented. In the same paragraph (page 1112, section 3) of Mark et al. (2010), the paper of 
Donoghue et al. (2010a) is criticised by writing that “several significant differences can be 
observed on the standard chromatograms and the results of the bone samples”. Such small 
differences are, however, valuable in showing that the extracts of bone samples are not 
contaminated by material from the standards. To suggest that such small differences might 
invalidate a diagnosis is contradictory to the arguments rehearsed elsewhere by Mark et al. 
(2011), which favoured a degree of diagenesis as a positive indication. Another criticism, 
levelled by Mark et al. (2011), concerns the presence of unknown peaks (labelled ‘?’), such as 
that in Figure 4 of Donoghue et al. (2010a); this particular unknown peak is in the same 
category as those shown in Fig. 2B (this Chapter) for the normal phase HPLC of mycolate 
derivatives from the Atlit-Yam skeletons (Hershkovitz et al., 2008). This unknown material, 
labelled ‘?’ in Fig. 2B, represents residual material from the initial reverse phase isolation of 
the total mycolates (Fig. 2A) and there is no necessity to know its identity. Indeed one 
purpose of the normal phase HPLC analysis (Fig. 2B) of the total mycolates is simply to 
remove this contaminating material and obtain purified -, methoxy- and ketomycolate 
classes for diagnostic reverse phase HPLC (Figs. 3A-C). Quite incredibly, the whole concept 
of normal phase chromatography is dismissed by Mark et al. (2011) as “not a ‘simple’ 
technique for the accurate separation of the components”; the reference (Neue, U.D., 1997. 
HPLC Columns. Wiley-VCN, New York.), quoted in support of this opinion, is only a 
document describing different types of chromatographic columns. However, normal phase 
chromatography is the bedrock of chemical research, being performed literally thousands of 
times each day in laboratories worldwide! 
 
Molecular Biomarkers for Ancient Tuberculosis 
 
23 
Mark et al. (2011) attempt to rationalize the disparate results presented in Mark et al. (2010, 
2011) by claiming that choice of MALDI-TOF mass spectral matrices dramatically influences 
the resulting spectrum. In Mark et al. (2011) (page 1113, section 3) it is stated that “The 
results with using fullerene as the matrix are incomparable with the mass spectra made by 
using CHCA or 2,5-DHB”. The essential conclusion is that the use of 2,5-DHB (2,5-
dihydroxybenzoic acid) results in spectra such as those in Fig. 5, but using fullerene 
produces the spectra shown in Fig. 4, for supposedly the same samples. The explanation 
given by Mark et al. (2011) (page 1117, section 3.2) for the spectra in Fig. 5 is “On these 
spectra the m/z 44.01 fragmentation pattern could not be observed, because the fullerene 
needed much higher laser energy for ionization than the 2,5-DHB matrix, thus the 
fragmentation was stronger in the first case”; this “first case” refers to the spectra shown in 
Fig. 4. This hypothesis is linked to the problem of explaining the 44 amu spacing of the 
peaks in the spectra (Fig. 4) recorded by Mark et al. (2010). According to Mark et al. (2010, 
2011) in profiles, such as that shown in Fig. 4A, a peak such as m/z 1406.3 should 
decarboxylate to give m/z 1362.3, losing 44 amu (CO2). How then does m/z 1362.3 lose a 
further 44 amu to produce m/z 1318, as it would have already lost its carboxyl group? This is 
a scientific non sequitur unworthy of further consideration. The suggestion by Minnikin et al. 
(2010) that the sequences of peaks in Fig. 4 are characteristic of contaminating polymers 
based on polyethylene glycol (PEG) (Keller et al., 2008; Schiller et al., 2004) is a much more 
plausible explanation. The proposal by Mark et al. (2011) is that an authentic MALDI-TOF 
spectrum (Fig. 5A) of standard mycolic acids, using 2,5-DHB as matrix, can be changed to 
that shown in Fig. 4A simply by using C60 fullerene as matrix. This is a revolutionary but 
unlikely proposal that, if it is to be believed, must be substantiated by systematic research. 
It is instructive to review the information required, using existing methods, to positively 
identify a mycolic acid pattern diagnostic for tuberculosis. The use of sequential 
reverse/normal/reverse phase HPLC analysis (Figs. 2 & 3) produces diagnostic patterns 
that, if the mycolates are undegraded, correlate well with standard material. Importantly, 
however, this protocol enables the key C80 (C78) -mycolates (Fig. 3A), C85 cis-
methoxymycolates (Fig. 3B) and C87 trans-ketomycolates (Fig. 3C) to be recognised. It must 
be understood that related mycolic acids are present in many mycobacteria, but extensive 
studies have been carried out (Minnikin et al. 2010; Watanabe et al. 2001, 2002) to establish 
that the above combination of principal mycolic acid components (Fig. 1A, Fig. 3) is 
characteristic for M. tuberculosis. Any diagnoses, using mass spectrometry or any other 
technique, must recognise the presence of these characteristic components. In the case of 
MALDI-TOF mass spectrometry, the key C80 (C78) -mycolates, C85 methoxymycolates and 
C87 ketomycolates can be recognised in standard extracts, as shown in Fig. 5A, but this 
pattern must be recognisable in extracts of archaeological material. The studies of Mark et al. 
(2010, 2011) claim that recognisable MALDI-TOF mass spectra have been obtained for 
mycolic acids extracted from archaeological material. Simple visual comparison of the 
authentic mycolic acid spectrum, shown in Fig. 5A, with the spectra exemplified in Figs. 4B 
& 5B, or any other spectra published in Mark et al. (2010, 2011), reveals nothing remotely 
comparable. The bottom line conclusion, therefore, is that Mark et al. (2010, 2011) have not 
identified M. tuberculosis mycolic acids in bone samples and literature reference to these 
papers must never support the claim that mycolic acids were detected.   
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Fig. 6. Selected ion monitoring negative ion-chemical ionization gas chromatography-mass 
spectrometry (NICI-GCMS) of pentafluorobenzyl esters from Coimbra skeleton C8, 
reproduced with permission from Redman et al. (2009). The C27 M/z 407 ion is for 
mycolipenic acid; the remainder are for the indicated C27 to C32 mycocerosic acids (Fig. 1B). 
The detailed analysis given above highlights the serious problem of perpetuating the 
conclusions in the papers of Mark et al. (2010, 2011). This demonstrates the potential risks 
and hazards for workers coming into a field of research and attempting to utilize a 
particular unproven technique to provide quick answers to a particular question. It is 
imperative that such researchers obtain basic knowledge and carry out the groundwork to 
enable them to perform effective objective science before producing premature publications. 
It is apparent, in the broad field of “archaeological science”, that some “artistic license” is 
more than acceptable to some researchers and certain editors of learned journals. In the 
present scenario, however, where specific chemical biomarkers are being used to diagnose 
ancient tuberculosis, there is absolutely no latitude in the identification of these distinct 
well-characterized chemical compounds. They are either positively identified or they are not 
and well-proven methods must be used along the guidelines advocated by Minnikin et al. 
(2010). Another most unsatisfactory aspect of the unconstructive publication by Mark et al. 
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(2011) is that, while the senior authors, on this paper, publically condemned the constructive 
paper of Minnikin et al. (2010), they were keen to collaborate in the use of HPLC analysis of 
mycolic acids to support their osteological studies. These collaborative enterprises, 
performed in good faith, have produced a joint publication (Lee et al., 2012) and joint 
conference presentations (Donoghue et al., 2010b; Pálfi et al., 2010). 
4.4 Mycocerosic and mycolipenic acid biomarkers for tuberculosis 
The current integrated strategy for the use of lipid biomarkers in tuberculosis diagnosis 
involves alkaline hydrolysis followed by conversion of released fatty acids to 
pentafluorobenzyl esters, which are separated into non-hydroxylated and mycolate fractions 
(Redman et al., 2009; Hershkovitz et al., 2008). The latter are derivatized and examined by 
HPLC, as described above but the former are analyzed by negative ion-chemical ionization 
gas chromatography-mass spectrometry (NICI-GCMS), using selected ion monitoring to 
detect the diagnostic mycocerosic and mycolipenic acids (Minnikin et al., 1993a). The 
protocol was applied to extracts of 49 skeletons from the 1837–1936 Coimbra Identified 
Skeletal Collection and an example of a positive tuberculosis diagnosis is shown in Fig. 6 
(Redman et al., 2009). The m/z 407 peak (10.45 min) corresponds to C27 mycolipenate (Fig. 
1B) with the others representing C27, C29, C30 and C32 mycocerosates (Fig. 1B). This pattern is 
characteristic of the MTBC complex (Minnikin et al., 1993a; Redman et al., 2009), a 
particularly diagnostic feature being the co-chromatography (11.36 min) of the C29 and C30  
acids (Fig. 6). This phenomenon results from the larger C30 acid being relatively more 
volatile due to the additional methyl branch (Fig. 1B). There was a 72% correlation of the 
mycocerosic acid profiles with the Coimbra burial records (Redman et al., 2009). 
Mycolipenic acids were detected only in skeletons, which were positive for mycocerosates 
but only in one third of these. Mycolipenic acids are components of pentaacyl trehalose 
glycolipids, which are likely to be degraded more rapidly than the phthiocerol 
dimycocerosate waxes (Minnikin et al., 2002). 
5. Conclusion 
After a slow beginning, almost two decades ago, characterization of M. tuberculosis aDNA 
has been systematically developed in a limited number of laboratories. The analysis of 
aDNA can provide a wealth of information about the particular strain of M. tuberculosis 
diagnosed, but the exact information is governed by the degree of preservation. The fact that 
aDNA analyses are now firmly established is due partly to technological advances but 
mainly due to established skills in key laboratories, built up over an extended period. 
Conclusive results can be obtained by aDNA analyses alone, but confirmatory biomarkers 
are valuable in completing the overall diagnosis. The tubercle bacillus and related 
mycobacteria are rich in unusual lipids, which are not produced in mammalian tissues. 
Building on sensitive methods, previously developed to detect lipid biomarkers for modern 
tuberculosis, and inspired by the initial aDNA results, mycolic acid biomarkers for 
tuberculosis were detected for the first time in archaeological bone just over a decade ago. 
After a flurry of initial studies, time was taken to explore more robust mycolic acid methods 
and expand the range of lipids to include characteristic mycocerosic and mycolipenic acids. 
Currently, aDNA and lipid analyses are established as a powerful combination to diagnose 
both tuberculosis and leprosy and, indeed, co-infections; these analyses can be performed on 
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the same sample. This is not a static situation, however, as new powerful methods are 
becoming available for analyses of aDNA and lipids; additionally, the range of lipids 
available for detection is by no means exhausted. 
The availability of established aDNA and biomarker protocols and expertise provides 
avenues into a range of interlocking research areas. As noted above, evolutionary pathways 
can be verified for tuberculosis, also providing evidence about virulence as the key lipid 
biomarkers are implicated in this process. The very existence of apparently intact key lipids 
in ancient samples is also of basic chemical interest; for example, the mycolic acids from the 
9,000 year old Atlit-Yam skeletons probably represent the oldest known cyclopropane rings! 
It is important also to study leprosy, as the evolutionary processes of these two 
mycobacterial diseases are fatally intertwined with many clear co-infections. The relative 
prevalence of tuberculosis and leprosy can give clear indications of the prevailing social 
environment. In tuberculosis/leprosy co-infections it is becoming possible to estimate the 
relative bacterial load in particular bones and thereby obtain indications regarding which 
disease was the immediate cause of death. For each disease and co-infections it will be 
instructive to examine bones throughout particular individual skeletons in order to gain 
information about dissemination. Evidence of tuberculosis and leprosy can be quite clear in 
the osteological record, with characteristic bone lesions and deformations and bone loss in 
the case of leprosy. Biomarker analysis can help illuminate and reinforce the diagnoses of 
skilled osteologists and compare bacterial loads in bones with and without disease 
indication. An appealing aspect of lipid biomarker analyses is the possibility of extracting 
the lipids with neutral solvents, avoiding any chemical or physical damage to particularly 
valuable bone samples. It must be borne in mind, however, that biomarker analyses for the 
diagnosis of ancient mycobacterial disease are currently sophisticated procedures, which 
cannot be easily attempted without time being spent in accumulating the necessary skills 
and experience. 
The evolution of life on earth is a complex web of competitive and/or symbiotic 
interactions. Humans, related primates and all mammals are dependent on a symbiosis with 
many microorganisms, whose cells outnumber those of the host. From the perspective of the 
microorganism, the mammalian host provides an ecological niche in which it can multiply 
and evolve to improve its prospects for survival. In some cases, the interaction of 
microorganisms with mammals is a rapid, pathogenic process resulting in the demise of the 
host and the infecting agent passes on to a new subject. Early hominids and humans with a 
hunter/gatherer lifestyle had a low population density, so an alternative relationship with 
slow-growing organisms such as the pathogenic mycobacteria, emerged. Such pathogens 
have a long-term relationship with their host, thus enabling persistence of the organism 
until transmission is possible. This is likely to occur at the extremes of life, when the host 
immune response is immature or less effective, and at times of physical or mental stress, 
often associated with war, famine, poverty or social unrest. This latter scenario is typical of 
the ancient scourges of tuberculosis and leprosy, caused by M. tuberculosis and M. leprae, 
respectively.  
Several decades ago, it appeared that BCG vaccination and combinations of effective drugs 
were conquering tuberculosis. However, declining vaccination efficacy, misuse of drug 
regimens and the rapid spread of HIV/AIDS-related immunodeficiency, together with 
increased urbanisation and population density, have provided the opportunity for 
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accelerated evolutionary changes to M. tuberculosis and the emergence of highly drug-
resistant and readily transmissible strains. Modern genomic approaches are also 
highlighting the great diversity existing within the inhomogeneous species labelled as M. 
tuberculosis. The developing science of paleogenomics is enabling approximate timelines for 
the evolution of M. tuberculosis to be laid down. The analysis of biomarkers is the prime way 
to verify the various proposed evolutionary pathways and to provide a direct timescale, 
rather than one inferred from bioinformatic analysis. In this review the contributions of 
ancient DNA (aDNA) and lipid biomarker analyses have been elaborated and critically 
assessed. 
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